to profit from unsound or presently un-validated genetic tests. The commercialization of genetic testing is well underway with companies offering sequencing services alongside a list of diseases to which one is susceptible for a price. There are also companies that claim to be able to optimize the treatment of addictions based on genetics (e.g. Salugen, http://www.salugen.com; NicoTest™, http://www.nicotest.com, accessed February 2010), and predict the risk of developing lung cancer (http://www.synergenz.com, accessed February 2010). Such ventures need to be regarded with caution, especially given the predictive power of genetic tests is still highly limited at best.
